Slingshot members are tracking this event:

FDA and EMA Accept for Review Biogen's (BIIB) Marketing Application for Nusinersen in Treatment of Spinal Muscular Atrophy (SMA)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 28, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ema, European Medicines Agency, Spinal Muscular Atrophy, Sma, Nusinersen, Priority Review, Marketing Authorization Application, Accelerated Assessment, Chmp